Cybin (NASDAQ:HELP) Stock Breaks Below Two Hundred Day Moving Average Following Weak Earnings

Cybin Inc. (NASDAQ:HELP – Get Free Report)’s stock price passed below its two hundred day moving average during trading on Monday after the company announced weaker than expected quarterly earnings. The stock has a two hundred day moving average of $7.81 and traded as low as $6.90. Cybin shares last traded at $7.67, with a volume of 12,808,773 shares traded.

The company reported ($1.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.74).

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the company. Barclays started coverage on Cybin in a research note on Friday, September 18th. They issued an “overweight” rating and a $35.00 price objective on the stock. Wells Fargo & Company raised their target price on Cybin from $16.00 to $22.00 and gave the company an “overweight” rating in a research note on Thursday, October 22nd. Wall Street Zen cut Cybin from a “sell” rating to a “strong sell” rating in a report on Saturday, November 7th. Finally, TD Cowen lifted their price target on Cybin from $8.00 to $62.00 and gave the company a “buy” rating in a report on Thursday, August 20th. Six research analysts have rated the stock with a Buy rating. According to MarketBeat, Cybin has an average rating of “Buy” and an average price target of $47.33.

Read Our Latest Research Report on Cybin

Insider Transactions at Cybin

In other Cybin news, CEO Michael Halstead bought 100,000 shares of the business’s stock in a transaction on Monday, September 21st. The shares were bought at an average cost of $13.47 per share, for a total transaction of $1,347,000.00. Following the transaction, the chief executive officer owned 168,568 shares in the company, valued at approximately $2,270,610.96. This trade represents a 145.84% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Greg Cavers bought 3,000 shares of Cybin stock in a transaction dated Tuesday, September 29th. The stock was acquired at an average cost of $12.91 per share, for a total transaction of $38,730.00. Following the purchase, the chief financial officer directly owned 3,000 shares in the company, valued at approximately $38,730. The trade was a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders bought 688,000 shares of company stock valued at $8,422,830. 15.00% of the stock is owned by company insiders.

Institutional Investors Weigh In On Cybin

A number of institutional investors and hedge funds have recently modified their holdings of the business. Integral Health Asset Management LLC bought a new stake in shares of Cybin during the 3rd quarter valued at $6,145,000. Royce & Associates LP acquired a new position in shares of Cybin in the 3rd quarter valued at $5,286,000. Great Point Partners LLC acquired a new position in shares of Cybin in the 3rd quarter valued at $3,944,000. Blue Owl Capital Holdings LP boosted its position in shares of Cybin by 381.2% in the 3rd quarter. Blue Owl Capital Holdings LP now owns 288,282 shares of the company’s stock worth $3,543,000 after purchasing an additional 228,371 shares during the last quarter. Finally, Pale Fire Capital SE bought a new position in shares of Cybin in the 2nd quarter worth $1,015,000. 17.94% of the stock is owned by institutional investors.

Cybin Stock Performance

The company has a 50-day moving average price of $11.15 and a 200-day moving average price of $7.81. The firm has a market capitalization of $612.14 million, a P/E ratio of -2.54 and a beta of 0.64.

About Cybin

(Get Free Report)

Cybin, which changed its name to Helus Pharma, is a clinical-stage biopharmaceutical company developing psychedelic-based treatments for mental health conditions. Its research focuses on designing and evaluating investigational compounds intended to address conditions including depression and anxiety disorders. The company’s pipeline has included CYB003, a deuterated psilocin analog being studied for major depressive disorder, and CYB004, an investigational DMT-based treatment studied for generalized anxiety disorder.

Further Reading

Receive News & Ratings for Cybin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cybin and related companies with MarketBeat.com's FREE daily email newsletter.